Robin Guo1, Mariel DuBoff1, Gowtham Jayakumaran2, Mark G Kris3, Marc Ladanyi4, Mark E Robson5, Diana Mandelker2, Marjorie G Zauderer6. 1. Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medicine, New York, New York. 4. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. 5. Breast Medicine Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 6. Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Weill Cornell Medicine, New York, New York. Electronic address: zauderem@mskcc.org.
Abstract
INTRODUCTION: Although next-generation sequencing (NGS) has brought insight into critical mutations or pathways (e.g., DNA damage sensing and repair) involved in the etiology of many cancers and has directed new screening, prevention, and therapeutic approaches for patients and families, it has only recently been used in malignant pleural mesotheliomas (MPMs). METHODS: We analyzed the blood samples from patients with MPM using the NGS platform MSK-IMPACT to explore cancer-predisposing genes. The loss-of-function variants or pathogenic entries were identified, and clinicopathologic information was collected. RESULTS: Of 84 patients with MPM, 12% (10 of 84) had pathogenic variants. Clinical characteristics were similar between cohorts, although patients with germline pathogenic variants were more likely to have more than two first-degree family members with cancer than those without germline mutations (40% versus 12%; Fisher's exact test, p < 0.05). Novel, deleterious variants in mesotheliomas included MutS homolog 3 (1% [one of 84]; 95% confidence interval [CI]: 0%-7%), breast cancer gene 1-associated ring domain 1 (1% [one of 84]; 95% CI: 0%-7%), and RecQ-like helicase 4 (2% [two of 84]; 95% CI: 0%-9%). Pathogenic variants previously reported on germline testing in patients with mesotheliomas were breast cancer gene 1-associated protein 1 (4% [three of 84]; 95% CI: 1%-10%), breast cancer gene 2 (1% [one of 84]; 95% CI: 0%-7%), and MRE11 homolog, double strand break repair nuclease (1% [one of 84]; 95% CI: 0%-7%). One patient (1% [one of 84]; 95% CI: 0%-7%) had a likely pathogenic alteration in SHQ1, H/ACA ribonucleoprotein assembly factor that has not been associated with a heritable susceptibility to cancer. CONCLUSIONS: Our study lends further support for the role of aberrations in DNA damage repair genes in the pathogenesis of MPMs and suggests that targeting the members of these pathways for screening and treatment warrants further study.
INTRODUCTION: Although next-generation sequencing (NGS) has brought insight into critical mutations or pathways (e.g., DNA damage sensing and repair) involved in the etiology of many cancers and has directed new screening, prevention, and therapeutic approaches for patients and families, it has only recently been used in malignant pleural mesotheliomas (MPMs). METHODS: We analyzed the blood samples from patients with MPM using the NGS platform MSK-IMPACT to explore cancer-predisposing genes. The loss-of-function variants or pathogenic entries were identified, and clinicopathologic information was collected. RESULTS: Of 84 patients with MPM, 12% (10 of 84) had pathogenic variants. Clinical characteristics were similar between cohorts, although patients with germline pathogenic variants were more likely to have more than two first-degree family members with cancer than those without germline mutations (40% versus 12%; Fisher's exact test, p < 0.05). Novel, deleterious variants in mesotheliomas included MutS homolog 3 (1% [one of 84]; 95% confidence interval [CI]: 0%-7%), breast cancer gene 1-associated ring domain 1 (1% [one of 84]; 95% CI: 0%-7%), and RecQ-like helicase 4 (2% [two of 84]; 95% CI: 0%-9%). Pathogenic variants previously reported on germline testing in patients with mesotheliomas were breast cancer gene 1-associated protein 1 (4% [three of 84]; 95% CI: 1%-10%), breast cancer gene 2 (1% [one of 84]; 95% CI: 0%-7%), and MRE11 homolog, double strand break repair nuclease (1% [one of 84]; 95% CI: 0%-7%). One patient (1% [one of 84]; 95% CI: 0%-7%) had a likely pathogenic alteration in SHQ1, H/ACA ribonucleoprotein assembly factor that has not been associated with a heritable susceptibility to cancer. CONCLUSIONS: Our study lends further support for the role of aberrations in DNA damage repair genes in the pathogenesis of MPMs and suggests that targeting the members of these pathways for screening and treatment warrants further study.
Authors: Ronja Adam; Isabel Spier; Bixiao Zhao; Michael Kloth; Jonathan Marquez; Inga Hinrichsen; Jutta Kirfel; Aylar Tafazzoli; Sukanya Horpaopan; Siegfried Uhlhaas; Dietlinde Stienen; Nicolaus Friedrichs; Janine Altmüller; Andreas Laner; Stefanie Holzapfel; Sophia Peters; Katrin Kayser; Holger Thiele; Elke Holinski-Feder; Giancarlo Marra; Glen Kristiansen; Markus M Nöthen; Reinhard Büttner; Gabriela Möslein; Regina C Betz; Angela Brieger; Richard P Lifton; Stefan Aretz Journal: Am J Hum Genet Date: 2016-07-28 Impact factor: 11.025
Authors: Michele Carbone; Prasad S Adusumilli; H Richard Alexander; Paul Baas; Fabrizio Bardelli; Angela Bononi; Raphael Bueno; Emanuela Felley-Bosco; Francoise Galateau-Salle; David Jablons; Aaron S Mansfield; Michael Minaai; Marc de Perrot; Patricia Pesavento; Valerie Rusch; David T Severson; Emanuela Taioli; Anne Tsao; Gavitt Woodard; Haining Yang; Marjorie G Zauderer; Harvey I Pass Journal: CA Cancer J Clin Date: 2019-07-08 Impact factor: 508.702
Authors: Lisa L Wang; Anu Gannavarapu; Claudia A Kozinetz; Moise L Levy; Richard A Lewis; Murali M Chintagumpala; Ramon Ruiz-Maldanado; Jose Contreras-Ruiz; Christopher Cunniff; Robert P Erickson; Dorit Lev; Maureen Rogers; Elaine H Zackai; Sharon E Plon Journal: J Natl Cancer Inst Date: 2003-05-07 Impact factor: 13.506
Authors: Reena Shakya; Matthias Szabolcs; Ellen McCarthy; Elson Ospina; Katia Basso; Subhadra Nandula; Vundavalli Murty; Richard Baer; Thomas Ludwig Journal: Proc Natl Acad Sci U S A Date: 2008-04-28 Impact factor: 11.205
Authors: Raunak Shrestha; Noushin Nabavi; Yen-Yi Lin; Fan Mo; Shawn Anderson; Stanislav Volik; Hans H Adomat; Dong Lin; Hui Xue; Xin Dong; Robert Shukin; Robert H Bell; Brian McConeghy; Anne Haegert; Sonal Brahmbhatt; Estelle Li; Htoo Zarni Oo; Antonio Hurtado-Coll; Ladan Fazli; Joshua Zhou; Yarrow McConnell; Andrea McCart; Andrew Lowy; Gregg B Morin; Tianhui Chen; Mads Daugaard; S Cenk Sahinalp; Faraz Hach; Stephane Le Bihan; Martin E Gleave; Yuzhuo Wang; Andrew Churg; Colin C Collins Journal: Genome Med Date: 2019-02-18 Impact factor: 11.117
Authors: Michael Offin; Soo-Ryum Yang; Jacklynn Egger; Gowtham Jayakumaran; Rowanne S Spencer; Jessica Lopardo; Garrett M Nash; Andrea Cercek; William D Travis; Mark G Kris; Marc Ladanyi; Jennifer L Sauter; Marjorie G Zauderer Journal: J Thorac Oncol Date: 2021-10-11 Impact factor: 15.609
Authors: Michele Carbone; Harvey I Pass; Guntulu Ak; H Richard Alexander; Paul Baas; Francine Baumann; Andrew M Blakely; Raphael Bueno; Aleksandra Bzura; Giuseppe Cardillo; Jane E Churpek; Irma Dianzani; Assunta De Rienzo; Mitsuru Emi; Salih Emri; Emanuela Felley-Bosco; Dean A Fennell; Raja M Flores; Federica Grosso; Nicholas K Hayward; Mary Hesdorffer; Chuong D Hoang; Peter A Johansson; Hedy L Kindler; Muaiad Kittaneh; Thomas Krausz; Aaron Mansfield; Muzaffer Metintas; Michael Minaai; Luciano Mutti; Maartje Nielsen; Kenneth O'Byrne; Isabelle Opitz; Sandra Pastorino; Francesca Pentimalli; Marc de Perrot; Antonia Pritchard; Robert Taylor Ripley; Bruce Robinson; Valerie Rusch; Emanuela Taioli; Yasutaka Takinishi; Mika Tanji; Anne S Tsao; A Murat Tuncer; Sebastian Walpole; Andrea Wolf; Haining Yang; Yoshie Yoshikawa; Alicia Zolondick; David S Schrump; Raffit Hassan Journal: J Thorac Oncol Date: 2022-04-21 Impact factor: 20.121
Authors: Elisabet Aliagas; Ania Alay; Maria Martínez-Iniesta; Miguel Hernández-Madrigal; David Cordero; Mireia Gausachs; Eva Pros; Maria Saigí; Sara Busacca; Annabel J Sharkley; Alan Dawson; Ramón Palmero; José C Ruffinelli; Susana Padrones; Samantha Aso; Ignacio Escobar; Ricard Ramos; Roger Llatjós; August Vidal; Eduard Dorca; Mar Varela; Montse Sánchez-Céspedes; Dean Fennell; Cristina Muñoz-Pinedo; Alberto Villanueva; Xavi Solé; Ernest Nadal Journal: Br J Cancer Date: 2021-09-29 Impact factor: 9.075
Authors: Lauren G Aoude; Vanessa F Bonazzi; Sandra Brosda; Kalpana Patel; Lambros T Koufariotis; Harald Oey; Katia Nones; Scott Wood; John V Pearson; James M Lonie; Melissa Arneil; Victoria Atkinson; B Mark Smithers; Nicola Waddell; Andrew P Barbour Journal: Sci Rep Date: 2020-10-19 Impact factor: 4.379